Gilead Sciences, Inc. (BIT:1GILD)

Italy flag Italy · Delayed Price · Currency is EUR
95.70
+1.18 (1.25%)
At close: Jul 14, 2025, 5:30 PM CET
1.25%
Market Cap116.76B
Revenue (ttm)26.59B
Net Income (ttm)5.52B
Shares Outn/a
EPS (ttm)4.38
PE Ratio21.16
Forward PE13.44
Dividend2.16 (2.25%)
Ex-Dividend DateMar 13, 2025
Volume105
Average Volume114
Open95.48
Previous Close94.52
Day's Range95.48 - 95.70
52-Week Range63.50 - 111.00
Beta0.31
RSI52.80
Earnings DateAug 1, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Sector Healthcare
Founded 1987
Employees 17,600
Stock Exchange Borsa Italiana
Ticker Symbol 1GILD
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD Financial Statements

News

There is no news available yet.